Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying…
1D
-2.7%
1W
-4.1%
1M
-34.4%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
08/12/2026 (in 52 days)
Volatility around earnings
Not enough history for an assessment
PRICE TARGET LOW
US$60.00
CONSENSUS
US$60.00
MEDIAN
US$60.00
PRICE TARGET HIGH
US$60.00
No current analyst ratings available.
FREE FLOAT
8.1%
FLOAT SHARES
3,365,556
AVG. DAILY VOLUME (30D)
555,927
Morningside Venture Investments Ltd
Morningside Venture Investments Ltd
Morningside Venture Investments Ltd
Morningside Venture Investments Ltd
Morningside Venture Investments Ltd
Apnimed, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kevin R. Lind, the company employs around 65 people.
The IPO was on 29/07/2026; the stock trades on NASDAQ under the ticker APMD.
The average price target is US$60.00, ranging from US$60.00 to US$60.00, with a median of US$60.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 08/12/2026.
No, Apnimed currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess Apnimed against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.